SML3682
ST2825
≥98% (HPLC), MyD88 dimerization inhibitor, powder
Synonym(s):
(2R,4′R,8′aR)-1-[2-[4-[[2-(2,4-Dichlorophenoxy)acetyl]amino]phenyl]acetyl]tetrahydro-6′-oxo-spiro[pyrrolidine-2,7′(6′H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4′-carboxamide, PAM4-SP19-Beta8-NH2, ST 2825, ST-2825
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C27H28Cl2N4O5S
CAS Number:
Molecular Weight:
591.51
UNSPSC Code:
51111800
NACRES:
NA.21
MDL number:
Product Name
ST2825, ≥98% (HPLC)
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Related Categories
Biochem/physiol Actions
Orally active peptidomimetic MyD88 homodimerization inhibitor with in vitro and in vivo efficacy against IL-1R and TLR9-dependent processes.
ST2825 is an orally active peptidomimetic of a heptapeptide structure in the MyD88 TIR BB-loop. ST2825 prevents IL-1beta-mediated activation of NF-kappaB by blocking MyD88 homodimerization and thereby the recruitment of IL-1 receptor-associated kinases IRAK1/4. ST2825 at 10 µg/mL completely suppresses 2.5 µg/mL TLR9 ligand ODN 2006-induced B-cell plasma cell differentation and antibodies production from PBMCs. ST2825 inhibits IL-1β-induced IL-6 production in mice (100 & 200 mg/kg p.o. prior to 20 µg/kg IL-1β i.p.) and protects against left ventricular (LV) dilatation and hypertrophy (25 mg/kg/day i.p.) in a murine model of nonreperfused acute myocardial infarction (AMI) in vivo.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Short-term MyD88 inhibition ameliorates cardiac graft rejection and promotes donor-specific hyporesponsiveness of skin grafts in mice
Transplant International : Official Journal of the European Society For Organ Transplantation, 29(8), 941-952 (2016)
Meng Qi et al.
Pharmacological research, 111, 509-522 (2016-07-20)
We previously reported the potent effect of dioscin against renal ischemia/reperfusion injury, but little is known about the role of dioscin in lipopolysaccharide (LPS)-induced inflammatory kidney injury. The present work aimed to investigate the effects and potential mechanisms of dioscin
Astragalus polysaccharides exerts immunomodulatory effects via TLR4-mediated MyD88-dependent signaling pathway in vitro and in vivo
Scientific Reports, 7, 44822-44822 (2017)
Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients
Rheumatology (Oxford, England), 49(12), 2281-2289 (2010)
Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse
Journal of Cardiovascular Pharmacology, 55(4), 385-390 (2010)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service